Is melatonin safe and appropriate for use in hepatic encephalopathy, and what dose is recommended?

Melatonin Should Not Be Used for Treatment of Hepatic Encephalopathy

Melatonin is not recommended for the treatment of hepatic encephalopathy and should be avoided in patients with cirrhosis, particularly those on multiple medications. The established first-line treatments remain lactulose and rifaximin, as supported by comprehensive clinical practice guidelines 1, 2, 3.

Why Melatonin Is Not Appropriate

Lack of Guideline Support

The most recent and authoritative clinical practice guidelines for hepatic encephalopathy management—including the 2022 EASL guidelines 2, 2023 French recommendations 3, and 2020 KASL guidelines 1—do not include melatonin as a treatment option. These guidelines comprehensively outline pharmacological options for managing overt HE, listing:

• Non-absorbable disaccharides (lactulose/lactitol)
• Rifaximin
• Branched-chain amino acids (BCAAs)
• L-ornithine-L-aspartate (LOLA)
• Albumin

Melatonin is conspicuously absent from all treatment algorithms 1, 2, 3.

Concerning Safety Profile in Cirrhosis

Recent evidence reveals significant hepatotoxicity concerns with high-dose melatonin in polymedicated patients. A 2026 clinical trial was prematurely halted after 3 out of 4 patients receiving 300 mg/day melatonin developed hypertransaminasemia 4. While this involved higher doses than typical sleep formulations, it highlights critical safety concerns:

• Drug-drug interactions: Melatonin shares hepatic CYP450 metabolic pathways with common medications used in cirrhosis (acetaminophen, omeprazole, NSAIDs, tizanidine) 4
• Metabolic pathway saturation: In patients with compromised liver function taking multiple medications, melatonin may contribute to hepatic overload 4
• Resolution upon discontinuation: The hepatotoxicity resolved after stopping melatonin, suggesting a causal relationship 4

Paradoxical Elevation in Hepatic Encephalopathy

Research demonstrates that melatonin levels are actually elevated in patients with hepatic encephalopathy, not deficient 5, 6, 7. Key findings include:

• Cirrhotic patients with HE have significantly higher morning melatonin levels (190 pg/mL) compared to healthy controls (23.88 pg/mL) 5
• Melatonin levels correlate with HE severity: patients with severe HE (West Haven grades III-IV) had levels of 280.98 pg/mL versus 45.62 pg/mL in those without HE 5
• Melatonin levels ≥85 pg/mL predict HE with 86.96% sensitivity and 100% specificity 5
• Patients with more severe cirrhosis (Child-Pugh >5) have disrupted melatonin secretion patterns 6

This elevation suggests melatonin may be part of the pathogenic mechanism of HE rather than a therapeutic target 7.

Established Treatment Algorithm

For Overt Hepatic Encephalopathy:

1. Identify and treat precipitating factors (infection, GI bleeding, constipation, dehydration, benzodiazepines, opioids) 1, 2, 3
2. Start lactulose immediately: 20-30 g orally 3-4 times daily, titrated to achieve 2-3 soft bowel movements per day 1, 3
3. Add rifaximin if inadequate response: 400 mg three times daily or 550 mg twice daily 1, 3
4. Consider adjunctive therapies: IV LOLA (30 g/day) for grades 1-2, oral BCAAs (0.25 g/kg/day), or albumin (1.5 g/kg/day) 1

For Prevention of Recurrent HE:

1. Lactulose as first-line secondary prophylaxis after first episode 2, 3
2. Add rifaximin if >1 additional episode occurs within 6 months despite lactulose 2, 3

Limited Role for Sleep Disturbances Only

The only potential role for melatonin in cirrhosis is for sleep disturbances in early-stage cirrhosis (Child-Pugh A or B) WITHOUT hepatic encephalopathy 8. A 2020 randomized trial showed 3 mg melatonin improved sleep quality in this specific population with acceptable short-term safety 8. However:

• This was a small study (60 completers) with short duration (2 weeks) 8
• Patients with any degree of hepatic encephalopathy were excluded 8
• Long-term safety data are lacking 9, 8
• The study specifically noted that "larger and longer-term studies to assess efficacy and safety are required before its clinical use can be recommended" 8

Critical Caveats

Do not confuse sleep disturbances with hepatic encephalopathy. If a cirrhotic patient has sleep problems:

• First rule out covert or overt HE using appropriate testing (Animal Naming Test, psychometric testing, West Haven criteria) 2
• If HE is present, treat with lactulose/rifaximin, not melatonin 1, 2, 3
• Only consider low-dose melatonin (3 mg) for isolated sleep disturbances in early cirrhosis without any HE 8

Avoid melatonin entirely in patients with:

• Any grade of hepatic encephalopathy
• Advanced cirrhosis (Child-Pugh C)
• Polypharmacy involving CYP450-metabolized drugs
• History of drug-induced liver injury